Human IFN-beta Antibody

Catalog #: MAB8145 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB8145-100
MAB8145-SP

SAVE +FREE SHIPPING with ACADEMIA23 (See Promo Details)

1 Image

View All Products for IFN-beta

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human IFN-beta Antibody Summary

Species Reactivity

Human

Specificity

Detects human IFN-beta in direct ELISAs.

Source

Monoclonal Mouse IgG₁ Clone # 1020344

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Chinese Hamster Ovary cell line CHO-derived human IFN-beta
Met22-Asn187
Accession # P01574

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Immunohistochemistry

5-25 µg/mL

See below

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Immunohistochemistry

View Larger

IFN‑ beta in Human Breast. IFN-beta was detected in immersion fixed paraffin-embedded sections of human breast using Mouse Anti-Human IFN-beta Monoclonal Antibody (Catalog # MAB8145) at 5 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in ductal cells. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Reconstitution Buffer Available

Reconstitution Buffer 1 (PBS)

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IFN-beta

Interferon beta (IFN-beta ), also known as fibroblast IFN, is a secreted, approximately 22 kDa member of the type I interferon family of molecules (1). Mature human IFN-beta shares 47% and 46% amino acid sequence identity with the mouse and rat proteins, respectively. Fibroblasts are the major producers of IFN-beta, but it can also be produced by dendritic cells, macrophages, and endothelial cells in response to pathogen exposure (2). It is transcriptionally regulated by TRAF3, IRF3, IRF7, and NF-kappa B (3, 4). Following secretion, IFN-beta signals through the heterodimeric IFN-alpha / beta Receptor and activates the JAK/STAT signaling pathway (5-8). IFN-beta -deficient mice show increased susceptibility to experimental autoimmune encephalomyelitis (EAE), a disease model of human multiple sclerosis (MS) (9). Furthermore, IFN-beta has been shown to suppress the Th17 cell response in both MS and EAE and has commonly been used as a treatment for MS (10-14).

References

González-Navajas, J.M. et al. (2012) Nat. Rev. Immunol. 12:125.
Reder, A.T. and X. Feng (2013) Front. Immunol. 4:281.
Schafer, S.L. et al. (1998) J. Biol. Chem. 273:2714.
Häcker, H. et al. (2006) Nature 439:204.
Honda, K. et al. (2006) Nat. Rev. Immunol. 6:644.
Platanias, L.C. (2005) Nat. Rev. Immunol. 5:375.
Fasler-Kan, E. et al. (1998) Eur. J. Biochem. 254:514.
Matikainen, S. et al. (1999) Blood 93:1980.
Teige, I. et al. (2003) J. Immunol. 170:4776.
Shinohara, M.L. et al. (2008) Immunity 29:68.
Guo, B. et al. (2008) J. Clin. Invest. 118:1680.
Ramgolam, V.S. and S. Markovic-Plese (2010) Endocr. Metab. Immune Disord. Drug Targets 10:161.
Martín-Saavedra, F.M. et al. (2008) Mol. Immunol. 45:4008.
Inoue, M. and M.L. Shinohara (2013) Immunology 139:11.